Testing an implanted vein sensor to guide care for people with heart failure
Tests a vein sensor to guide care in adults with heart failure.
Key facts
- Who runs it
- Foundry Innovation & Research 1, Limited (FIRE1)
- Where
- Baton Rouge, Boston, Chapel Hill, Chula Vista, Cincinnati, Colombus, Columbia, Dallas, Greenville, Jacksonville, Kansas City, New York, Omaha, Philadelphia, Plano, Round Rock, Sacramento, Sioux Falls, Tampa, Temple, Toledo, and Tulsa, United StatesSee the 25 sites
- Trial code
- Registry title
- NORM-HF Pivotal Study
- Status
- Recruiting
- People taking part
- 800 people, planned
- Started
- 29 May 2026
- Expected to end
- Dec 2033
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- IVC Sensor
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure (NYHA class II or III) who take a daily loop diuretic and whose heart failure blood test (NT-proBNP) is raised. Half will get an implanted sensor in a large vein (the IVC) to guide care.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Heart failure for more than 90 days, NYHA class II or III. Class II needs a heart failure flare-up in the past 12 months. Class III can join with or without one, if the NT-proBNP level is high enough.
- Earlier treatment
- On the best medicines they can tolerate for at least 30 days. A loop diuretic of 40mg or more furosemide (or equivalent) daily for the 2 weeks before screening. The dose must be able to go up at least 1.5 times.
- Biomarker or test result
- NT-proBNP of at least 1000 pg/mL in class II, or at least 600 pg/mL in class III with a recent flare-up. With atrial fibrillation or flutter: at least 1,600 pg/mL, or at least 900 pg/mL. Vein diameter in the sensor zone of 14mm to 28mm, zone length at least 60 mm.
Main reasons for not taking part
- End stage heart failure or class IV heart failure
- Kidney function eGFR below 25 mL/min/1.73m2, or on dialysis
- Abdominal circumference over 143 cm (4 ft 8 in)
- Pregnant, nursing, or planning a pregnancy within 1 year
- Cannot take dual antiplatelet medicine for at least 30 days after the implant
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Adults 18 years of age or older
- Provide informed consent for participation in the clinical study and be willing and able to comply with the required assessments, treatment instructions, and clinical follow-up visits according to the specified schedule
- Patients meeting diagnostic criteria for HF diagnosis for greater than 90 days and are on optimally tolerated medical therapy for at least 30 days, as recommended according to current AHA/ACC/HFSA or ESC HF guidelines with any intolerance or contraindications documented, regardless of ejection fraction, as evidenced by meeting either 3a, 3b OR 3c criterion below:; NYHA functional class II with documented HF decompensation within the previous 12 months resulting in a primary HF hospitalization, HF treatment in a hospital day-care setting or unscheduled visit to a healthcare provider for administration of an intravenous diuretic to treat HF AND NT-proBNP ≥1000 pg/mL. For those patients presenting with atrial fibrillation or flutter, NT-proBNP ≥1,600 pg/mL; OR; NYHA functional class III with documented HF decompensation within the previous 12 months resulting in a primary HF hospitalization, HF treatment in a hospital day-care setting or unscheduled visit to a healthcare provider for administration of an intravenous diuretic to treat HF AND NT-proBNP ≥ 600 pg/mL. For patients presenting with atrial fibrillation or flutter, NT-pro BNP ≥900 pg/mL; OR; NYHA functional class III AND NT-proBNP ≥1000 pg/mL. For patients presenting with atrial fibrillation or flutter, NT-proBNP ≥1,600 pg/mL
- Patients must be prescribed a daily dose of loop diuretic of 40mg or more furosemide, or equivalent, for the two weeks prior to screening
- Patients must be able to have their daily dose of loop diuretic be increased by at least 1.5 times
- IVC diameter within the landing zone of between 14mm and 28mm
- Minimum IVC landing zone length of 60 mm
- Patients have sufficient cellular and/or Wi-Fi Internet coverage at home and can access the internet on a phone or a computer at home
Who cannot take part
- Presence of advanced end stage HF, suggested by but not limited to:; Persistent NYHA functional class IV HF (ACC/AHA/ESC); Current treatment with intravenous vasopressors or inotropes; Received, or are likely to receive in the next 6 months, an advanced therapy (e.g., mechanical circulatory support or cardiac transplant or previously listed for transplant); Receiving end of life HF care
- Major non-heart-failure-related CV event (i.e., unstable angina, Type 1 myocardial infarction (MI), percutaneous coronary intervention, open heart surgery, or stroke, etc.) within 90 days prior to consent
- Implanted with Cardiac Resynchronization Therapy (CRT)-Pacemaker (CRT-P), CRT Defibrillator (CRT-D), Cardiac Contractility Modulation (CCM), or implantable neuromodulation devices used to treat HF symptoms within 90 days prior to consent
- Unable to tolerate dual antiplatelet therapy for at least 30 days following implant of the respective sensor or unable to continue oral anticoagulation if currently prescribed
- Patients with pulmonary embolism, venous thrombosis, or thromboembolism in the 6 months prior to screening and/or with ongoing concerns of hypercoagulability due to underlying conditions e.g., thrombophilia
- Severe right sided valvular disease or a right sided mechanical valve
- Presence of end stage hypertrophic cardiomyopathy, end stage restrictive cardiomyopathy, end stage pericardial constriction, end stage cardiac amyloidosis, or other infiltrative cardiomyopathy such as hemochromatosis or sarcoidosis
- Significant congenital heart disease that would impair ability to implant the IVC sensor or complicate interpretation of the reading (e.g., fontan circulation physiology)
- Any condition that, in the opinion of the Investigator, would not allow for implantation or utilization of IVC sensor
- Patients with active systemic infection at screening
- Patients with hypersensitivity or allergy to antiplatelet agents or Sensor components (Nitinol, Polyurethane [PU], Nylon, Polyethylene Terephthalate [PET], and Gold) or contrast media that will not be managed with a clinical site-specific allergy protocol
- Patients with an estimated Glomerular Filtration Rate (eGFR) < 25 mL/min/1.73m2 or receiving ultrafiltration or chronic dialysis
- Patients with abdominal circumference of greater than 143 cm (56 inches) at screening
- Implanted or planned implantation of a pulmonary artery pressure (PAP) monitor
- Patients that are pregnant, nursing or planning a pregnancy within 1 year of screening
- Anticipated life expectancy < 12 months due to another etiology or severity of HF
- Current or anticipated participation in any other clinical study during the duration of this study not pre-approved by the Sponsor
- Patients with an in vivo IVC filter, abnormal IVC or femoral venous anatomy, known congenital malformation or absence of IVC, or occlusive or free-floating thrombus in the IVC, iliac, or common femoral veins
- Patients who have procedures planned that require venous femoral access within 3 months of the Sensor implantation
Where in United States
- Cardiovascular Institute of the SouthBaton Rouge, United StatesContact: Troy PenzTaking people
- Massachusetts General HospitalBoston, United StatesContact: Troy PenzTaking people
- University of North CarolinaChapel Hill, United StatesContact: Troy PenzTaking people
- Cardiovascular Institute of San DiegoChula Vista, United StatesContact: Troy PenzTaking people
- Christ Hospital LindnerCincinnati, United StatesContact: Troy PenzTaking people
- Ohio State University HospitalColombus, United StatesContact: Troy PenzTaking people
- Prisma Health MidlandsColumbia, United StatesContact: Troy PenzTaking people
- Baylor Scott & White - DallasDallas, United StatesContact: Troy PenzTaking people
- Prisma Health-UpstateGreenville, United StatesContact: Troy PenzTaking people
- University of Florida Health JacksonvilleJacksonville, United StatesContact: Troy PenzTaking people
- Saint Luke's Hospital of Kansas CityKansas City, United StatesContact: Troy PenzTaking people
- Columbia University Irving Medical Center/New York Presbyterian HospitalNew York, United StatesContact: Troy PenzNot yet recruiting
- NYU LangoneNew York, United StatesContact: Troy PenzNot yet recruiting
- University of Nebraska Medical CenterOmaha, United StatesContact: Troy PenzTaking people
- Thomas Jefferson University HospitalPhiladelphia, United StatesContact: Troy PenzTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Troy PenzTaking people
- Baylor Scott & White - PlanoPlano, United StatesContact: Troy PenzTaking people
- Baylor Scott & White - Round RockRound Rock, United StatesContact: Troy PenzTaking people
- UC DavisSacramento, United StatesContact: Troy PenzTaking people
- North Central Heart - Avera HospitalSioux Falls, United StatesContact: Troy PenzTaking people
- Baycare Health SystemTampa, United StatesContact: Troy PenzTaking people
- Tampa General HospitalTampa, United StatesContact: Troy PenzTaking people
- Baylor Scott & White - TempleTemple, United StatesContact: Troy PenzTaking people
- ProMedica Toledo HospitalToledo, United StatesContact: Troy PenzTaking people
- Saint Francis Health SystemTulsa, United StatesContact: Troy PenzTaking people
About the trial
What the trial wants to find out
This is an international, multi-center, prospective, randomized, open-label blinded endpoint study designed to demonstrate that use of the FIRE1 NORM™ System in the management of New York Heart Association Class II/III HF patients is superior for reducing the combined endpoint of worsening HF events and cardiovascular mortality compared to standard of care treatment. Patients will be randomized in a 1:1 ratio to receive either NORM™ System and guided heart failure management (intervention group) or usual standard of care with guided heart failure management (control group).
The 2 groups in the trial
- InterventionTreatment being tested
implant of the sensor, physician directed, patient self-management and guideline directed heart failure management
Treatment: IVC Sensor
- ControlNo study treatment, for comparison
control arm - standard medical therapy with guideline directed heart failure management
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- NORM-HF (NORM-guided Congestion Management in Heart Failure) Pivotal Study
- Plain-language title
- Testing an implanted vein sensor to guide care for people with heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 October 2026